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Background: One possible barrier to effective diabetes self-management is hypoglycaemia associated with diabetes
medication. The current study was conducted to characterize hypoglycaemic events among UK patients with type
2 diabetes (T2D) treated with antihyperglycaemic medications, and assess the relationship between experience of
hypoglycaemic events and health outcomes, including glycaemic control, health-related quality of life, impairment
to work and non-work activities, treatment satisfaction, adherence to treatment, fear of hypoglycaemia, and
healthcare resource use.
Methods: An online survey of 1,329 T2D patients in UK drawn from an opt-in survey panel was conducted in
February of 2012 with monthly follow-up questionnaires for five months. Measures included self-reported
HbA1c, EQ-5D, Work Productivity and Activity Impairment questionnaire, Diabetes Medication Satisfaction Tool,
Morisky medication adherence scale, the Hypoglycaemia Fear Survey (revised), and self-reported healthcare
resource use. Comparisons were conducted using t-tests and chi-square tests for continuous and categorical
variables, respectively.
Results: Baseline comparisons showed that worse HbA1c, greater diabetes-related healthcare resource use,
greater fear of hypoglycaemia, and impaired health outcomes were associated with experience of hypoglycaemia in
the four weeks prior to baseline. Longitudinal results were similar in direction but differences on few measures were
significant.
Conclusions: In real-world UK T2D patients, hypoglycaemia is associated with worse self-reported glycaemic control,
behaviours that contribute to worse glycaemic control, and impairment in patient-reported outcomes.
Keywords: Hypoglycaemia, Hypoglycaemic events, Health related quality of life, Hypoglycaemia fear, Treatment
satisfactionBackground
Numerous studies have demonstrated that intensive
control of blood glucose reduces the development and
progression of vascular complications in diabetes [1-7].
The balance of randomized trial evidence suggests inten-
sive glucose control reduces risk for some cardiovascular
disease outcomes [8], even while there are notable ex-
ceptions to this pattern [1,9,10].* Correspondence: Jeffrey.vietri@kantarhealth.com
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treatment often do not achieve adequate control, a result
observed in both clinical trials and observational studies
[11-14]. One potential reason for inadequate control is
the experience or fear of hypoglycaemia, which can lead
to non-adherence or non persistence to treatment, and
other behaviours to raise blood glucose, such as increased
consumption of carbohydrates, avoidance of exercise, and
reducing the dose of antihyperglycaemic medications
[15-18]. Further, physicians see hypoglycaemia as a limit-
ing factor in how aggressively they can use therapies suchl Ltd. This is an open access article distributed under the terms of the Creative
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diabetes (T2D) [19].
The relationship between hypoglycaemic events (HEs)
and outcomes in patients with T2D has been investigated
in several recent studies, including a cross-sectional sur-
vey of 2,074 patients with T2D in the United States (US)
on oral antihyperglycaemic medication [20]. Those who
reported symptoms of hypoglycaemia at least ‘some of
the time’ on the hypoglycaemia items of the Diabetes
Symptom Measure [21] were less likely to be at their
treatment goal for glycosylated haemoglobin (HbA1c),
as well as less likely to know their HbA1c.
Another large (n = 1,984) survey of US patients with
T2D found worse self-reported health status as severity
of HE increased from mild (no interruption of activities)
through moderate, severe, and very severe (required
medical attention) [22]. The same study found a rela-
tionship between frequency of HEs and increased
worry about hypoglycaemia. Likewise, linking patient
surveys with healthcare claims data demonstrates that
patients with T2D treated with pharmacotherapy who
experience HEs have higher medical costs, more fear
of hypoglycaemia, and impaired health status relative
to patients without HEs [23].
Further, a multi-country study in Asia (n = 2257)
assessed the relationship between experience of symp-
toms of hypoglycaemia and HbA1c, health status, and
worry about hypoglycaemia [24]. As in the studies above,
hypoglycaemia symptoms were associated with worse
health status and more worry about hypoglycaemia. This
study also measured HbA1c, and an unadjusted analysis
showed 0.24% lower average HbA1c among those with
HE in the 6 months prior. Patient-perceived symptom
severity was not associated with differences in HbA1c,
though the pattern of means suggests more severe HE
may be associated with higher HbA1c.
Despite these recent additions to the literature, gaps
remain, especially within individual countries. It is im-
portant to understand how blood glucose levels, par-
ticularly the longer-term blood glucose levels reflected
in HbA1c, are related to the experience of HEs, a relation-
ship seldom assessed. Therefore, the objective of current
study was to assess the link between HEs, HbA1c, patient-
reported outcomes, and healthcare resource use among
patients with T2D in the United Kingdom (UK).
Methods
Potential respondents were identified through the 2011
5EU National Health and Wellness Survey (NHWS)
and the diabetes chronic ailment panel of Light Speed
Research in the UK. The 5EU NHWS is a proprietary sur-
vey of adults (≥18 years) conducted by Kantar Health in
France, Germany, Italy, Spain, and UK, which collects data
approximately every 18 months to provide timely patient-reported information on a broad range of health condi-
tions. The UK portion of the 5EU NHWS survey includes
15,000 respondents representative of the UK population
in terms of age and gender. The Light Speed chronic ail-
ment panel consists of individuals who have previously
indicated they suffer from diabetes. All panel partici-
pants were originally sourced from a general (i.e., not
healthcare-specific) internet survey panel whose members
are recruited through opt-in emails, co-registration with
panel partners, e-newsletter campaigns, online banner
placements, and both internal and external affiliate net-
works. All panelists explicitly consented to become panel
members, registered through unique email addresses, and
completed in-depth demographic registration profiles.
Panelists from the Light Speed chronic ailment group
and respondents to the 5EU NHWS survey residing in the
UK who indicated that they had diabetes were sent an
invitation email with a link to the informed consent of the
survey (n = 7,144). Those who gave consent (n = 3,224;
45%) were then screened for a physician diagnosis of T2D
(n = 2,396), and current use of a prescription medicine for
their T2D (n = 2,071). In order to ensure adequate num-
bers of insulin users, a quota of 300 respondents using in-
sulin was included, which resulted in 295 T2D patients
using only oral medication being excluded from the sur-
vey. The remaining patients (n = 1,776) were directed to
the baseline questionnaire.
The study was designed as a longitudinal survey with
six assessment points from February 2012-July 2012,
each separated by four weeks. Respondents were in-
formed that they would receive a small incentive for
completion of each assessment point, either in the form
of points that could be exchanged for merchandise or a
monetary payment. Incentives increased from approxi-
mately £2.50 for the baseline survey to £12.75 for the
final assessment to discourage attrition. Respondents
were notified of the availability of the questionnaire via
email at the opening of each assessment point and had
one week to complete the questionnaire, and all those
who completed the baseline were invited to participate
in each follow-up. Up to four reminder emails were sent
over the course of the week the survey was available.
However, attrition over the duration of the study resulted
in only 34% (n = 451) of the baseline sample reporting at
the last follow-up, and only 12% (n = 155) of baseline re-
spondents completed all follow-up waves. Therefore, the
current study primarily focuses on cross-sectional analysis
of baseline data.
The study protocol and questionnaire was approved by
Essex IRB, a commercial IRB based in the United States.
Measures
All measures were by self-report with the exception of
geographic region, which was extracted from survey panel
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age, gender, employment status, annual household in-
come, and UK region. Height and weight were used to cal-
culate body mass index (BMI), and respondents indicated
whether they currently smoke cigarettes, as well as the
number of days they exercised “vigorously” in the past 30.
Respondents were also asked to indicate whether they had
been diagnosed with various chronic conditions, which
were used to calculate the Charlson comorbidity index
(CCI) [25].
Questions regarding their experience with HEs in-
cluded whether they had ever experienced a HE, the
number of events they had experienced in the prior six
months, and the number of HEs they had experienced in
the prior four weeks. These were categorised by the level
of assistance needed; self-managed, requiring assistance
from someone else (not a healthcare professional), and
requiring assistance from a medical professional.
Those who reported ever experiencing a HE answered
questions characterizing the most recent event. These
included how the event was detected (symptoms con-
firmed by a blood glucose reading, symptoms not con-
firmed with a blood glucose reading, and a low blood
glucose reading in the absence of symptoms), the per-
ceived trigger of the event, the assistance required, the cir-
cumstances (what they were doing at the time) and what
actions they (or someone else) took in response to the HE.
Glycaemic control was assessed through the most re-
cent self-reported HbA1c. Respondents could use either
percentage or mmol/mol formats (here converted to
percentage for reporting). Those who could not provide
an HbA1c reading were presented with a series of ranges
of HbA1c values and asked to indicate the range (and
approximate date) of their most recent results. Because
HbA1c is only typically assessed between one and four
times per year in the UK, values provided at the first
follow-up survey were used to supplement the values
provided at baseline for those who did not provide a
baseline value.
Multiple existing patient-reported outcome question-
naires were administered as part of the survey:
Health status was assessed using the EQ-5D ques-
tionnaire [26]; a widely used preference-based, generic
(as opposed to disease-specific) questionnaire. The ques-
tionnaire consists of 2 parts – a population-weighted
health state index score and a self-perceived current
health score. Only the health state index score was
used in this study. This score is calculated based on re-
sponses to 5 dimensions of health (mobility, self-care,
usual activities, pain/discomfort and anxiety/depression)
and then weighted using UK population weights to pro-
vide a single value on a scale from −0.594 to1 with higher
scores indicating better health utility (negative values indi-
cate a health state worse than dead).The Work Productivity and Activity Impairment
(WPAI) questionnaire [27] was used to measure impair-
ment to work productivity and the activities of daily liv-
ing. Four subscales (absenteeism, presenteeism, overall
work impairment, and activity impairment) are gener-
ated in the form of percentages (0 to 100%), with higher
values indicating greater impairment during the preceding
seven days. All respondents completed the general health
version, which queries work and activity impairment due
to general health. Those reporting a hypoglycaemic event
in the preceding seven days also completed the Specific
Health Problem version to assess impairment due to
hypoglycaemia.
Treatment satisfaction was measured using the Diabetes
Medication Satisfaction Tool (DMSAT). The DMSAT [28]
measures satisfaction with the patient’s diabetes medica-
tions regimen. The instrument consists of 16 items which
create 4 subscales (3 items for wellbeing, 3 items for med-
ical control, 5 items for lifestyle, and 5 items for conveni-
ence) and a total score. Responses are summed and
converted to a score from 0 to 100 for each subscale and
overall, with higher scores representing more satisfaction.
For the purposes of this study, only the overall score
was used.
Adherence to medication was measured using the
Morisky medication adherence scale (MMAS) [29,30].
The MMAS is a generic self-reported, medication-taking
behaviour scale, consisting of four items which are
summed to give a range of scores from high adherence (0)
to low adherence (4). After discussion with the scale au-
thor, the scale was modified, creating one version asses-
sing oral antidiabetic medication and a second assessing
insulin (administered only to patients taking insulin).
The Hypoglycaemia Fear Survey, revised (HFS-II) was
used to measure fear of hypoglycaemia [31]. This is a
33-item questionnaire with two subscales that measure
1) behaviours to avoid hypoglycaemia and its negative
consequences and 2) worries about hypoglycaemia and
its negative consequences. Responses are made on a 5-
point Likert scale where 0 = Never and 4 = Always. The
behaviour, worry, and total scores were all included in
analyses. Behaviour subscale items include items that
would not necessarily contribute to poorer glycaemic
control (e.g., avoiding being alone) and five behaviors
that would: eating large snacks, keeping blood glucose
(BG) above 150, keeping BG higher than normal in so-
cial situations, keeping BG higher than normal during
important activities, and reducing insulin dose. These
items were included in the behavioral subscale and total
scale scores, but also analyzed separately, dichotomized as
never engaging in that behaviour versus engaging in the
behaviour during the recall period. Though the standard
recall period for the HFS-II is six months, the measure
was modified to better suit the design of the current study
Table 1 Demographics and general health characteristics









Decline to answer 153 11.5%
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the scale author.
In addition, respondents were asked to indicate the
number of times they visited different types of health-
care providers in relation to their diabetes care during
the four weeks prior as a measure of healthcare resource
use. These included the physician who primarily man-
ages their T2D (may be primary or secondary care),
other physicians, and other providers (nurses, dieticians,
podiatrists, etc.). These were combined with the primary
physician visits to provide a count of the total provider
visits. Another item queried the number of times the re-
spondent was hospitalized in the preceding four weeks.General health
BMI (continuous) 31.9 6.4
BMI (categories)
Underweight 8 0.6%
Normal weight 119 9.0%
Overweight 362 27.2%
Obese 683 51.4%
Decline to answer 157 11.8%
Exercised* 599 45.1%
Currently smoke 158 11.9%
CCI 1.6 1.5
*Note: Exercised indicates exercising “vigorously” at least once for 20 minutes
during the preceding month. CCI: Charlson comorbidity index.Statistical analysis
The total sample was characterized using mean and
standard deviation for continuous variables and fre-
quency and percentages for categorical variables. These
were followed with a comparison between the group of
patients who reported having a hypoglycaemic event in
the four weeks preceding baseline and the group who
did not report an event, with comparisons planned for
the outcomes listed above. For continuous variables, an
independent groups t-statistic was used for the compari-
son (with a Welch-Satterthwaite approximation to the
degrees of freedom when the homogeneity assumption
violated). A chi-square test was used for categorical vari-
ables. P-values < 0.05 were considered statistically signifi-
cant. No adjustment for multiplicity was made.Results
A total of 1,329 respondents completed the baseline sur-
vey; follow-up surveys were completed by 836, 759, 765,
511, and 451 respondents, respectively. Demographics
and general health characteristics are presented in
Table 1. Consistent with the T2D population, the sample
was predominantly late middle age, male, and overweight.
All the regions of the UK were represented, roughly in
proportion to the general population. Clinical characteris-
tics are presented in Table 2. Respondents on average re-
ported diabetes duration of 9.6 years, and most were free
of complications. The majority were using only oral anti-
hyperglycaemic medication. Of those who provided a
value for HbA1c (29.6%), the mean value was 7.3%. When
considering both those who provided a value for HbA1c
(n = 393) and those who could not provide a value but se-
lected their HbA1c from a range (n = 495), 32.6% reported
an HbA1c of 7.0% or below. An additional 33.2% did not
provide either an exact or approximate HbA1c value.
The prevalence of ≥1 HE within the 4-week period
was 27.5% for the sample overall, higher among insulin
users (n = 301) than those not using insulin (n = 1,028)
(43.5% vs. 22.8%, p < 0.0001).Characteristics of most recent HE
Among those experiencing ≥1 HE, most (61.2%) had
symptoms of hypoglycaemia with a low blood glucose
reading, but 27.7% did not test blood glucose during the
most recent HE. 5.5% were only aware of their most re-
cent event because of a blood-glucose test, and 5.5% had
a normal blood glucose reading during the event they
considered to be hypoglycaemic in nature.
Among those experiencing symptoms during their
most recent HE, the most common were trembling/
shaking (55.3%), dizziness/light-headedness (53.6%), sweat-
ing (38.6%), weakness (34.1%) and uneasiness/ill feeling
(32.6%). Most patients (89.8%) reported experiencing mul-
tiple symptoms.
Most HEs were attributed to lack of timely eating or
inappropriate food choices. The most commonly en-
dorsed reasons were delayed eating (29.6%), irregular or
too few carbohydrates (24.8%) and skipped meals or
snacks (20.4%). Too much exercise (15.6%) and stress
(13.2%) were also commonly implicated triggers. 4.6% at-
tributed the incident to a new antidiabetic medication,
and 10% of insulin users experiencing a HE indicated a
miscalculation of insulin dose.
The most common circumstance for the most recent
HE was while doing household jobs or shopping (22.1%),
followed by relaxing (watching TV, reading; 21.5%), and
Table 2 Diabetes characteristics of sample (n = 1,329)
n/mean %/SD
Duration of diabetes (years) 9.6 7.0
HbA1c (among those providing a number; n = 393) 7.25% 1.5%
HbA1c in ranges






10.6% or above 34 2.6%
Unknown 441 33.2%
Medications
Oral (OAD) only 971 73.1%
Non-insulin injectable (NII) only 16 1.2%
Insulin (IN) only 79 5.9%
OAD & NII 41 3.1%
OAD & IN 174 13.1%
NII & IN 7 0.5%
OAD, NII, & IN 41 3.1%
Complications
Macular edema/diabetic retinopathy 117 8.8%
Kidney disease 51 3.8%
Foot or leg ulcer 60 4.5%
Neuropathic pain 220 16.6%
End organ damage 18 1.4%
None 989 74.4%
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(9.3%) and while sleeping (9.3%). Only 8.1% of the most
recent HEs were while at work, though much of the
sample was not employed. Of those employed, at work
was the most commonly reported location (23.0%).
Most of the most recent HEs described were self-
managed (85.2%), but 10.1% required assistance from
another non-medical person and 4.7% needed medical
assistance. The most typical response was to eat or drink
something (76.4%) and/or take glucose tablets (21.7%),
or discontinue physical activity (9.4%). Some patients
began checking their blood glucose more frequently
(16.8%) and (3.4%) had their doctor change their treat-
ment regimen as a result of the most recent HE.
Outcome differences associated with HE
Comparisons between those with ≥1 HE in the prior
four weeks and those without an event during the same
period of time revealed numerous differences (Table 3).
Of primary interest, among the portion of the sampleproviding a value for HbA1c at baseline or the first
follow-up survey, those with ≥1 HE in the preceding
four week had significantly higher A1c values than those
who did not (p < 0.01). The EQ-5D health state index
score was lower (worse) among those experiencing ≥1
HE in 4 weeks prior to the first survey relative to those
without (p < 0.0001). Differences in work impairment be-
tween the two groups were also apparent. Employed re-
spondents who experienced ≥1 HE in the month leading
to the baseline survey reported approximately double
the work impairment in the prior seven days experi-
enced by those employed respondents without ≥1 HE,
an absolute difference of 18.7%. Impairment to non-
work activities during the same period was also higher
among those with ≥1 HE, equating to a mean absolute
difference of 12.5%. Those who had experienced ≥1 HE
in the past week attributed considerable impairment to
the event, 24.6% overall work impairment among the
employed, and 44% impairment in non-work activities
(not presented).
Satisfaction with medication and adherence to medica-
tions were also different based on the experience of ≥1
HE in the prior four weeks. Medication satisfaction was
lower among those who experienced ≥1 HE in the 4 weeks
prior to survey (.08 on a 0–1.0 scale; p < 0.0001). Adher-
ence to oral medication was only marginally lower
(p = .06) in those with at ≥1 HE in the prior four weeks,
and adherence to insulin was significantly lower among
insulin users experiencing ≥1 HE during that time relative
to insulin users who did not (p < 0.0001).
Experience of ≥1 HE in the past month was associated
with increased healthcare resource use relative to those
who did not. Patients who experienced ≥1 HE visited the
physician (who primarily manages their T2D) almost
twice as often as those who did not. A similar increase
was seen in the number of total diabetes-related health-
care visits. There were relatively few diabetes-related
hospitalizations reported among either group, but the
average among those reporting ≥1 HE was more than
twice that of those who did not report any HEs.
Fear of hypoglycaemia was significantly higher among
those experiencing ≥1 HE for the total score as well as
both subscales (p < 0.0001). Respondents with ≥1 HE re-
ported performing a range of specific glucose-raising be-
haviours on the HFS-II (Table 4).
Baseline data of those completing all surveys was ex-
plored for differences between those reporting ≥1 HE
during the course of the study (n = 83) and those who
did not experience HE (n = 72). This analysis included
only a small and self-selected subsample of the baseline
survey respondents, but is included here to facilitate hy-
pothesis generation for future research (Table 5). The
mean difference in HbA1c averaged across each wave
(0.3%) was consistent with the baseline difference, but
Table 3 Bivariate health outcome differences between patients reporting hypoglycaemia and patients not
experiencing hypoglycaemia
Hypoglycaemia (n = 365) No hypoglycaemia (n = 964)
n/mean %/SD n/mean %/SD p-value
HbA1c (n =139 & 254) 7.51 1.60 7.11 1.39 0.0095
EQ-5D Index (n = 360 & 953) 0.56 0.39 0.69 0.34 <0.0001
Work and activity impairment
Overall work impairment (n = 141 & 270) 35.3% 35.8% 16.6% 25.6% <0.0001
Activity impairment 44.5% 32.8% 32.0% 31.7% <0.0001
Treatment satisfaction 0.67 0.17 0.75 0.18 <0.0001
Adherence to treatment
Oral medications (n = 316 & 911) 0.81 1.01 0.69 0.94 0.0573
Insulin (n = 131 & 170) 0.95 1.25 0.60 0.96 0.0076
Diabetes-related healthcare resource use
4-week PCP visits 0.73 1.05 0.38 0.66 <0.0001
4-week total visits 1.82 2.50 0.92 1.51 <0.0001
4-week hospitalizations 0.16 0.52 0.06 0.31 0.0006
Hypoglycaemia fear
Worry 15.60 12.51 6.53 9.24 <0.0001
Behaviour 17.81 15.39 6.58 10.95 <0.0001
Total 33.40 25.46 13.11 18.46 <0.0001
Note: When fewer than the full sample are included in a comparison, sample sizes are indicated in parentheses for those experiencing hypoglycaemia and not
experiencing hypoglycaemia in the four weeks prior to the survey, respectively. Lower HbA1c is associated with better outcomes and fewer complications. Higher
EQ-5D scores indicate more preferred health status, with 1.0 equivalent to perfect health. Work impairment and activity impairment ranged from 0 to 100%, with
lower numbers indicating less impairment. Treatment satisfaction ranges from 0 to 1.0, with higher numbers indicating grater satisfaction. Adherence to treatment
ranges from 0 to 4, with higher numbers indicating less adherence. Hypoglycemia fear ranges from 0 to 72 for Worry, 0 to 60 for behaviour, and 0 to 132 for the
total score, with higher scores indicating more fear of hypoglycaemia.
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for those with ≥1 HE during the study was .09 points
worse that of those who completed the study without
experiencing any HE, a difference which approached
statistical significance (p =0.07) and would exceed the
0.07 threshold for minimally important difference [32].
There was greater activity impairment among the group
that experienced ≥1 HE, but no significant difference in
work impairment. The 8% decrement in satisfaction with
diabetes medication observed in the baseline comparison
was observed in the longitudinal sample. Greater use




Ate large snacks 283
Kept glucose above 150 225
Kept glucose higher than normal in social situations 199
Kept glucose higher than normal in important activities 205
Reduced insulin dose (n = 131 & 170) 91reporting ≥1 HE, although this difference was limited
to the total number of provider visits. The most significant
differences in the longitudinal subsample were of average
scores on the HFS-II, all of which remained significantly
worse (all p <0.001), with total scores 15 points higher
among those with ≥1 HE.
Discussion
The current study found that HEs are common in pa-
tients with T2D in the UK, with 23% of those using oral
medication (without insulin) experiencing a HE during a
four week period, while the rate among insulin usersithin last 4 weeks by experience of hypoglycaemia during
ia (n = 365) No hypoglycaemia (n = 964)
% n % p-value
77.5% 497 51.6% <0.0001
61.6% 352 36.5% <0.0001
54.5% 189 19.6% <0.0001
56.2% 197 20.4% <0.0001
69.5% 88 51.8% 0.0021
Table 5 Average outcomes among those completing all study surveys
Hypoglycaemia (n = 83) No hypoglycemia (n = 72)
Mean SD Mean SD p-value
HbA1c (LOCF; n = 53 & 37) 7.35% 1.68% 7.05% 1.83% 0.4389
Health-related quality of life
EQ-5D index 0.62 0.35 0.71 0.29 0.0669
Work and activity impairment
Overall work impairment 19.6% 21.9% 10.8% 22.5% 0.1620
Activity impairment 41.2% 29.2% 28.9% 29.4% 0.0102
Treatment satisfaction 0.72 0.16 0.80 0.15 0.0011
Diabetes-related healthcare resource use
4-week diabetes PCP visits 0.43 0.48 0.31 0.41 0.0948
4-week total diabetes provider visits 1.07 1.24 0.69 0.88 0.0286
4-week total hospitalizations 0.05 0.15 0.06 0.24 0.9661
Hypoglycaemia fear
Worry 11.59 9.72 4.45 5.31 <0.0001
Behaviour 11.61 11.74 3.26 5.72 <0.0001
Total 23.19 20.25 7.71 9.47 <0.0001
Note: LOCF, last observation carried forward.
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in the prior week attributed substantial impairment to
both work and activities of daily living. Comparisons of
those who experienced ≥1 HE in the four weeks prior to
the survey also had worse outcomes, including health
status and treatment satisfaction, more diabetes-specific
healthcare resource use, greater impairment of non-
work activities, and more fear of hypoglycaemia, includ-
ing a greater likelihood of reporting behaviours that
would raise their blood glucose levels. Insulin users who
reported ≥1 HE also reported less adherence to their in-
sulin than users who were free of HEs; the relationship
between HEs and adherence was not observed in oral
medications, perhaps because patients understand the
potential for insulin to cause hypoglycaemia, and per-
haps due to the injectable mode of administration, which
is more aversive than swallowing a pill and also enables
dose reduction.
Although the 0.3% difference in HbA1c is modest rela-
tive to the effect of antihyperglycaemic medications [33],
it indicates that HEs may be predictive of higher HbA1c
when linked to the results indicating HEs to be associ-
ated with behaviour likely to increase glucose levels.
The other differences between the groups are larger in
magnitude. The mean difference in EQ-5D index of 0.13
points represents an effect of d = 0.36, equal or larger to
some guidelines for a clinically meaningful effect [34].
This difference was equal or slightly larger than the
0.08-0.10 difference reported in similar studies in other
geographies [20,22]. This finding may be particularly im-
portant, given the established predictive relationshipbetween EQ-5D scores and both complications and mor-
tality in diabetes [33,35]. The magnitude of some of the
other disparities are larger still; applying the standard
Cohen’s d effect size guidelines [36], the 0.08 point dif-
ference in treatment satisfaction would be interpreted
as a moderate (d = 0.44) effect, while the differences
in hypoglycaemia fear are large, ranging from d = 0.82
for worry to d = 0.90 for the total score.
One finding of this study that is at odds with previous re-
search is the relationship between HEs and HbA1c.
Though few studies have investigated the connection be-
tween HEs and glycaemic control, an Asian study measur-
ing HbA1c from blood draw found lower HbA1c among
those with hypoglycaemia [24]. It is unclear why the find-
ings are different, but it could be that the relationship be-
tween hypoglycaemia and glycaemic control cannot be
clearly ascertained from cross-sectional analyses, and there
are reasons to believe that both relationships are true
under certain circumstances. Indeed, those who maintain
low blood glucose are, in a sense, closer to hypoglycaemia
than those whose blood glucose is consistently high, and
previous research has demonstrated that individuals with
lower glycosylated hemoglobin levels are indeed at greater
risk of HEs [7,9,37,38]. However, those who experience
HEs may adjust their regimen in an attempt to prevent
subsequent HEs, potentially raising their HbA1c in the
process [39,40]. It could also be that relationship between
glycaemic control and HEs differs according to region due
to cultural or lifestyle factors.
Another interesting finding was the location of the
HEs, which were most commonly reported as happening
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during physical activity such as exercise or playing sports
which might be expected to result in low blood glucose
levels. Unfortunately, this is likely due to lack of physical
activity among the sample; less than half of the sample
reported one or more days in the previous month during
which they exercised for 20 minutes or more, and items
asking about the context of the HE referred only to the
most recent episode to maximize the accuracy of the re-
call. If individuals exercise infrequently, they have lim-
ited opportunities to have a HE during exercise.
There are some limitations of the study that should be
acknowledged. An important limitation shared by this
and other real-world studies on HEs is the reliance on a
sample other than a population-based probability sam-
ple; in this case a sample from an opt-in survey panel.
Therefore, this sample may under- or overestimate the
prevalence of HEs in the UK T2D population. This also
makes it difficult to determine the extent to which the
other results of the present study generalize to the
broader UK T2D population, though the sample appears
representative on several important characteristics. The
use of the online survey panel also limited follow-up re-
minders to email which, along with the limited response
window, likely contributed to the relatively low response
rate for the follow-up waves. Another limitation is the
lack of HbA1c results for the majority of the sample,
which limited statistical power and raises the concern
that this portion of the sample may be different in im-
portant ways from the participants who were unable to
provide an HbA1c value. Finally, the analyses here are
primarily cross-sectional and correlational in nature.
Comparisons were not adjusted for potential differences
between the groups in terms of demographic, disease, or
treatment characteristics, and differences between the
groups other than the presence of HEs may explain the
differences in outcomes.
While not a limitation per se, an important point to
consider is that HE status relied on self-report. Patient
characterizations of their most recent HE revealed that
many did not test blood glucose during their episode,
and a few claimed to have normal blood glucose levels
during their HE, raising the question of whether all
those in the HE group experienced a HE as defined by
the American Diabetes Association criteria [41]. From
the standpoint of behaviour, this may not be important;
if the perception that one is experiencing HEs result in
less effective disease management, then whether the
blood glucose level is actually low is of little importance.
However, if the response to the HE is to switch the pa-
tient to a medication that has a lower risk of HEs, such
a switch may not have the intended result because what
the patient perceived as hypoglycaemia was something
else.Despite these caveats, the current study makes some
meaningful contributions to our understanding of HEs
among UK patients with T2D, estimating the four-week
prevalence of HEs among those on antihyperglycaemic
medication, characterizing the events, and documenting
the differences between patients with and without recent
HEs. Unlike previous some previous studies that in-
cluded patients with type 1 diabetes, the current study
focused entirely on T2D. The sample was considerably
larger than the UK T2D samples in previous studies,
and the survey included a broader array of patient-
reported outcomes. The present study also confirms
findings from other studies in other geographies regard-
ing the relationship between HEs and impairment to
work and non-work activities, satisfaction with medica-
tion, healthcare utilization, and fear of hypoglycaemia.
The findings underscore the importance of considering
risk of HEs when planning a patient’s treatment regimen,
ensuring patients are educated about HEs, and encour-
aging regular testing of blood glucose.
Conclusion
HEs are unpleasant, relatively common among those be-
ing treated for T2D, and are feared by patients even if
they have not had recent experience of one. Those who
report recently experiencing ≥1 HE have worse health out-
comes than those who do not. In addition to impaired
outcomes such as health status and treatment satisfaction,
experiencing ≥1 HE is associated with worry and perform-
ing behaviours designed to increase blood glucose, with
the likely eventual result being impaired glucose control,
an increased risk of complications, worsening health out-
comes for the patient, and increased burden on the
healthcare system. Future research should assess whether
interventions aimed at reducing HEs and fear of HEs also
improve outcomes.
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